Cadila: Warning letters pose fresh challenges
It received the letters from USFDA for compliance-related issues at its Moraiya formulation plant and Zyfine active pharmaceutical ingredients facility in Ahmedabad01-01-2016
01-01-2016
Cadila gets FDA warning letter on two plants; stock dips nearly 17%
Cadila receives warning letter from FDA for violating manufacturing standards at its Moraiya formulation facility and Ahmedabad oncology API facility31-12-2015
Updates on Warning Letter - US FDA
Cadila Healthcare Ltd has informed BSE that :"The Company has received a Warning Letter issued by the US FDA relating to its Moraiya formulation facility and Ahmedabad API facility (Zyfine).We take quality and compliance matters very seriously and stand by our commitment to fully comply with cGMP quality standards across all our facilities. The Company is working hard to ensure that the commitments made to the US FDA are fully completed....31-12-2015
Will Cadila, Holcim deal get FIPB nod?
The Foreign Investment Promotion Board on Wednesday will take up 16 investment proposals including that of Cadila Healthcare and Holcim (lndia). Cadila Healthcare is seeking approval for fresh equ...16-12-2015
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Life Insurance Corporation of India has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201115-12-2015
Authorised KMPs to determine materiality of events/information
Cadila Healthcare Ltd has informed BSE regarding "Authorised Key Managerial Personnel to determine materiality of events/information".15-12-2015
Mankind Pharma launches anti-diabetic product Dynaglipt
Zydus Cadila also launches its generic Tenglyn tablets, Gliptins, in the Indian market for Rs 7 per tablet Mankind Pharma has launched an anti-diabetic product Dynaglipt targeting the middle class and rural diabetic patients. The company has launched anti-diabetic product for the diabetic patients targeting the middle class and rural diabetic patients, so as to []24-11-2015
Drug launch to keep Cadila Health in focus
Zydus Cadila has launched tablet Tenglyn, the generic version of oral anti-diabetic drug Gliptins, in India. Tenglyn, priced at 7 a tablet, is almost a sixth of the price at which Gliptins was in...21-11-2015
Zydus launches 'Tenglyn', the most affordable gliptin for diabetics in India
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated November 20, 2015 titled "Zydus launches 'Tenglyn', the most affordable gliptin for diabetics in India".20-11-2015
Zydus to start phase-II clinical trials for Saroglitazar in US
Cadila Healthcare (Zydus Cadila) today announced the US drug regulator has endorsed company's plan to initiate a phase 2 clinical trial of Saroglitazar18-11-2015